Company intelligence / Profile preview

Hangzhou Geber Biopharmaceutical

Hangzhou, Zhejiang, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Geber Bio is a clinical-stage biotechnology company focused on the discovery and development of next-generation targeted protein degradation (TPD) therapies. Utilizing its proprietary GlueTacs platform, the company designs molecular glues and PROTACs to target previously undruggable proteins associated with cancer and autoimmune diseases. Geber Bio's lead programs focus on novel E3 ligase ligands and degraders for hematologic malignancies and solid tumors. The company is led by a team of experts in protein degradation and is backed by prominent life science investors.

Therapeutic areas: ImmunologyOncology
Modalities: Molecular glue therapyProteolysis-targeting chimera therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Hangzhou Geber Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Geber Biopharmaceutical.

Explore the full profile